Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Sionna Therapeutics, Inc.NASDAQ: SION
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $18.96M rose 38.7% year over year, ahead of the +7.9% change in trailing-twelve-month research & development. Sequentially, it rose 25.0% from the prior quarter. Over 3 fiscal years it compounded at +20.3% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +38.7% holds above the trailing-twelve-month pace of +7.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 60.26M USD
- Year-over-year change
- +5.2%
- 3-year CAGR
- +20.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 60.26M | +5.2% |
| FY2024 | 2024-12-31 | 57.29M | +41.0% |
| FY2023 | 2023-12-31 | 40.63M | +17.4% |
| FY2022 | 2022-12-31 | 34.61M | — |
Research & Development vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 research & development of $65.56M is the 10th highest of the 11 companies compared; the peer median is $211.41M.
- Its year-over-year change of +7.9% is the 9th highest of 11, against a peer median of +32.6%.
- Over three fiscal years its annual growth of +20.3% compares with a peer median of +22.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.51B | +1655.5% | -13.1% | 942.7% | |
| LTM Jun 2026 | $467.76M | -32.9% | +13.3% | — | |
| LTM Sep 2026 | $283.32M | +31.2% | +43.9% | 252960.7% | |
| LTM Jun 2026 | $261.87M | +51.3% | +45.5% | — | |
| LTM Sep 2026 | $236.54M | +35.6% | +95.7% | — | |
| LTM Sep 2026 | $186.28M | +1.9% | +20.1% | 274.5% | |
| LTM Mar 2026 | $127.65M | +60.8% | +33.1% | 590.6% | |
| LTM Mar 2026 | $114.57M | +28.4% | +7.1% | 572.9% | |
| LTM Mar 2026 | $74.32M | +33.9% | +24.8% | 17.4% | |
| LTM Mar 2026 | $65.56M | +7.9% | +20.3% | — | |
| LTM Mar 2026 | $32.2M | +26.3% | +14.1% | 10.2% | |
| Peer median (excluding SION) | $211.41M | +32.6% | +22.5% | 572.9% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 668K | 647K |
| Gross Profit | 0 | 0 | (668K) | (647K) |
| Gross Margin | — | — | — | — |
| Research & Development | 34.61M | 40.63M | 57.29M | 60.26M |
| Selling, General & Admin | 6.77M | 9.71M | 13.27M | 28.72M |
| Operating Expenses | 41.37M | 50.33M | 69.89M | 88.34M |
| Depreciation & Amortization | 122K | 583K | 668K | 647K |
| EBITDA | (40.12M) | (46.68M) | (61.02M) | (74.62M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (41.37M) | (50.33M) | (70.56M) | (88.98M) |
| Operating Margin | — | — | — | — |
| Interest Income | 1.13M | 2.77M | 8.17M | 13.3M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.13M | 3.07M | 8.87M | 13.71M |
| Income Before Tax | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | (40.24M) | (47.26M) | (61.69M) | (75.27M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.91) | (1.07) | (1.40) | (1.88) |
| EPS (Diluted) | (0.91) | (1.07) | (1.40) | (1.88) |
| Weighted Avg Shares | 44.12M | 44.12M | 44.12M | 39.96M |
| Weighted Avg Shares (Diluted) | 44.12M | 44.12M | 44.12M | 39.96M |
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.